Re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder" by Strawn et al.-Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder

Affiliations

• ¹ Center for Inpatient Psychotherapy and Crisis Intervention, Paracelsus Medical University Salzburg, Salzburg, Austria.
• ² Research and Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Ilford, United Kingdom.
• ³ Division of Psychiatry, University College London, London, United Kingdom (honorary affiliation).
• ⁴ Department of Applied Psychology, Zurich University of Applied Sciences, Zurich, Switzerland.